Karen Aiach

Last updated on 2017-02-15T14:05+0300.

About this image

sign

Quotes... Extracted quotes from

Karen Aiach added : “The company keeps focusing its resources on its strategic objective of becoming a leading gene therapy technological platform targeting CNS diseases. Our priority remains to execute on our existing pipeline with the completion of the LYS-SAF302 pivotal trial, the respective completion and initiation of the recruitment of the safety and efficacy cohorts of the LYS-GM101 clinical trial for the treatment of GM1 gangliosidosis and move forward our pre-clinical programs in Fragile X and nGaucher/Parkinson. We are also constantly looking for opportunities to further expand our pipeline with new CNS gene therapy assets” External link

businesswire Friday, January 14, 2022 8:17:00 AM EAT

Karen Aiach added : “The company keeps focusing its resources on its strategic objective of becoming a leading gene therapy technological platform targeting CNS diseases. Our priority remains to execute on our existing pipeline with the completion of the LYS-SAF302 pivotal trial, the respective completion and initiation of the recruitment of the safety and efficacy cohorts of the LYS-GM101 clinical trial for the treatment of GM1 gangliosidosis and move forward our pre-clinical programs in Fragile X and nGaucher/Parkinson. We are also constantly looking for opportunities to further expand our pipeline with new CNS gene therapy assets” External link

eagletribune Thursday, January 13, 2022 11:01:00 AM EAT

Karen Aiach added : “The company keeps focusing its resources on its strategic objective of becoming a leading gene therapy technological platform targeting CNS diseases. Our priority remains to execute on our existing pipeline with the completion of the LYS-SAF302 pivotal trial, the respective completion and initiation of the recruitment of the safety and efficacy cohorts of the LYS-GM101 clinical trial for the treatment of GM1 gangliosidosis and move forward our pre-clinical programs in Fragile X and nGaucher/Parkinson. We are also constantly looking for opportunities to further expand our pipeline with new CNS gene therapy assets” External link

4-traders Thursday, January 13, 2022 10:06:00 AM EAT

Karen Aiach added : “2021 is off to a good start, and this year will be marked by a sustained focus on executing on our clinical programs and further developing our pre-clinical pipeline” External link

4-traders Wednesday, March 31, 2021 9:04:00 AM EAT

Karen Aiach said : “We are very pleased to receive this IND clearance for LYS-GM101 which completes the MHRA approval received a few weeks ago. It represents a major milestone that marks our second CNS gene-therapy program to enter into a global clinical trial” External link

4-traders Friday, February 12, 2021 10:04:00 AM EAT

Karen Aiach said : “This trial builds on Lysogene’s considerable expertise for AAV gene therapy and clinical development. Since the most damaging effects of GM1 gangliosidosis occur in the brain and spinal cord, LYS-GM101 will be administered into a cerebrospinal fluid-filled space at the back of the head called the cisterna magna so that enough therapy reaches those tissues. I expect the study to provide us with data demonstrating the transformative potential of LYS-GM101” External link

4-traders Monday, January 11, 2021 10:21:00 AM EAT

Karen Aiach said : "This trial builds on Lysogene's considerable expertise for AAV gene therapy and clinical development. Since the most damaging effects of GM1 gangliosidosis occur in the brain and spinal cord, LYS-GM101 will be administered into a cerebrospinal fluid-filled space at the back of the head called the cisterna magna so that enough therapy reaches those tissues. I expect the study to provide us with data demonstrating the transformative potential of LYS-GM101" External link

finanznachrichten-en Monday, January 11, 2021 10:14:00 AM EAT

Karen Aiach added : “I want to express my deep thanks to all our loyal shareholders, and assure them that we remain fully focused on our mission during this Covid19 crisis, namely to keep our employees safe and bring therapeutic solutions as soon as possible to children suffering from MPSIIIA and GM1 gangliosidosis” External link

4-traders Wednesday, April 22, 2020 9:10:00 AM EAT

Karen Aiach said : "We are honored to welcome Carole on our Board of Directors. Carole's extensive experience in executive management and corporate governance coaching, combined with her knowledge in the Life Sciences field will be an invaluable asset to Lysogene's fast growing management and executive teams," External link

finanznachrichten-en Thursday, September 26, 2019 8:48:00 PM EAT

Karen Aiach concludes : "On behalf of the Lysogene Board of Directors and executive leadership team, I would like to sincerely thank Annette for her significant contribution to the Company's development and for her thoughtful counsel," External link

finanznachrichten-en Thursday, September 26, 2019 8:48:00 PM EAT

Karen Aiach said : "Having launched our Phase 2-3 clinical trial in MPS IIIA, enrolled half of the intended study population and completed our two-year natural history study to be used as the control group, so far 2019 has been a year of significant progress. MPS IIIA is a devastating disease in young children, for which there is no currently approved treatment option. Lysogene, our partner Sarepta and the patient and physician commitment and investment to deliver potentially transformative therapies to these patients is unparalleled," External link

finanznachrichten-en Thursday, September 5, 2019 7:51:00 PM EAT

Karen Aiach said : “Having launched our Phase 2-3 clinical trial in MPS IIIA, enrolled half of the intended study population and completed our two-year natural history study to be used as the control group, so far 2019 has been a year of significant progress. MPS IIIA is a devastating disease in young children, for which there is no currently approved treatment option. Lysogene, our partner Sarepta and the patient and physician commitment and investment to deliver potentially transformative therapies to these patients is unparalleled,” External link

4-traders Thursday, September 5, 2019 7:37:00 PM EAT

Karen Aiach said : "The first patient dosed in the AAVance trial is an important step in addressing this relentlessly progressing neurodegenerative disease. Our aim is to stabilize or improve the clinical status of patients with MPS IIIA by providing a permanent source of functional enzyme in the brain," External link

finanznachrichten-en Friday, February 15, 2019 12:42:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
directrice générale100.00%FR02/15/201715/02/2017
Names Lang Count
Karen AiachEN50.00%
Karen AiachFR50.00%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Wednesday, July 6, 2022

6:13:00 AM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

Karen Aiach

Last updated on 2017-02-15T14:05+0300.

About this image

sign

Quotes... Extracted quotes from

Karen Aiach added : “The company keeps focusing its resources on its strategic objective of becoming a leading gene therapy technological platform targeting CNS diseases. Our priority remains to execute on our existing pipeline with the completion of the LYS-SAF302 pivotal trial, the respective completion and initiation of the recruitment of the safety and efficacy cohorts of the LYS-GM101 clinical trial for the treatment of GM1 gangliosidosis and move forward our pre-clinical programs in Fragile X and nGaucher/Parkinson. We are also constantly looking for opportunities to further expand our pipeline with new CNS gene therapy assets” External link

businesswire Friday, January 14, 2022 8:17:00 AM EAT

Karen Aiach added : “The company keeps focusing its resources on its strategic objective of becoming a leading gene therapy technological platform targeting CNS diseases. Our priority remains to execute on our existing pipeline with the completion of the LYS-SAF302 pivotal trial, the respective completion and initiation of the recruitment of the safety and efficacy cohorts of the LYS-GM101 clinical trial for the treatment of GM1 gangliosidosis and move forward our pre-clinical programs in Fragile X and nGaucher/Parkinson. We are also constantly looking for opportunities to further expand our pipeline with new CNS gene therapy assets” External link

eagletribune Thursday, January 13, 2022 11:01:00 AM EAT

Karen Aiach added : “The company keeps focusing its resources on its strategic objective of becoming a leading gene therapy technological platform targeting CNS diseases. Our priority remains to execute on our existing pipeline with the completion of the LYS-SAF302 pivotal trial, the respective completion and initiation of the recruitment of the safety and efficacy cohorts of the LYS-GM101 clinical trial for the treatment of GM1 gangliosidosis and move forward our pre-clinical programs in Fragile X and nGaucher/Parkinson. We are also constantly looking for opportunities to further expand our pipeline with new CNS gene therapy assets” External link

4-traders Thursday, January 13, 2022 10:06:00 AM EAT

Karen Aiach added : “2021 is off to a good start, and this year will be marked by a sustained focus on executing on our clinical programs and further developing our pre-clinical pipeline” External link

4-traders Wednesday, March 31, 2021 9:04:00 AM EAT

Karen Aiach said : “We are very pleased to receive this IND clearance for LYS-GM101 which completes the MHRA approval received a few weeks ago. It represents a major milestone that marks our second CNS gene-therapy program to enter into a global clinical trial” External link

4-traders Friday, February 12, 2021 10:04:00 AM EAT

Karen Aiach said : “This trial builds on Lysogene’s considerable expertise for AAV gene therapy and clinical development. Since the most damaging effects of GM1 gangliosidosis occur in the brain and spinal cord, LYS-GM101 will be administered into a cerebrospinal fluid-filled space at the back of the head called the cisterna magna so that enough therapy reaches those tissues. I expect the study to provide us with data demonstrating the transformative potential of LYS-GM101” External link

4-traders Monday, January 11, 2021 10:21:00 AM EAT

Karen Aiach said : "This trial builds on Lysogene's considerable expertise for AAV gene therapy and clinical development. Since the most damaging effects of GM1 gangliosidosis occur in the brain and spinal cord, LYS-GM101 will be administered into a cerebrospinal fluid-filled space at the back of the head called the cisterna magna so that enough therapy reaches those tissues. I expect the study to provide us with data demonstrating the transformative potential of LYS-GM101" External link

finanznachrichten-en Monday, January 11, 2021 10:14:00 AM EAT

Karen Aiach added : “I want to express my deep thanks to all our loyal shareholders, and assure them that we remain fully focused on our mission during this Covid19 crisis, namely to keep our employees safe and bring therapeutic solutions as soon as possible to children suffering from MPSIIIA and GM1 gangliosidosis” External link

4-traders Wednesday, April 22, 2020 9:10:00 AM EAT

Karen Aiach said : "We are honored to welcome Carole on our Board of Directors. Carole's extensive experience in executive management and corporate governance coaching, combined with her knowledge in the Life Sciences field will be an invaluable asset to Lysogene's fast growing management and executive teams," External link

finanznachrichten-en Thursday, September 26, 2019 8:48:00 PM EAT

Karen Aiach concludes : "On behalf of the Lysogene Board of Directors and executive leadership team, I would like to sincerely thank Annette for her significant contribution to the Company's development and for her thoughtful counsel," External link

finanznachrichten-en Thursday, September 26, 2019 8:48:00 PM EAT

Karen Aiach said : "Having launched our Phase 2-3 clinical trial in MPS IIIA, enrolled half of the intended study population and completed our two-year natural history study to be used as the control group, so far 2019 has been a year of significant progress. MPS IIIA is a devastating disease in young children, for which there is no currently approved treatment option. Lysogene, our partner Sarepta and the patient and physician commitment and investment to deliver potentially transformative therapies to these patients is unparalleled," External link

finanznachrichten-en Thursday, September 5, 2019 7:51:00 PM EAT

Karen Aiach said : “Having launched our Phase 2-3 clinical trial in MPS IIIA, enrolled half of the intended study population and completed our two-year natural history study to be used as the control group, so far 2019 has been a year of significant progress. MPS IIIA is a devastating disease in young children, for which there is no currently approved treatment option. Lysogene, our partner Sarepta and the patient and physician commitment and investment to deliver potentially transformative therapies to these patients is unparalleled,” External link

4-traders Thursday, September 5, 2019 7:37:00 PM EAT

Karen Aiach said : "The first patient dosed in the AAVance trial is an important step in addressing this relentlessly progressing neurodegenerative disease. Our aim is to stabilize or improve the clinical status of patients with MPS IIIA by providing a permanent source of functional enzyme in the brain," External link

finanznachrichten-en Friday, February 15, 2019 12:42:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
directrice générale100.00%FR02/15/201715/02/2017
Names Lang Count
Karen AiachEN50.00%
Karen AiachFR50.00%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Wednesday, July 6, 2022

6:13:00 AM EAT


Quotes... Explore Relations


EMM Visual Explorer